Declining Rates of Fatal and Nonfatal Intracerebral Hemorrhage: Epidemiological Trends in Australia

Melina Gattellari, PhD; Chris Goumas, MPH (Hons); John Worthington, MBBS

Background—A recent systematic review of epidemiological studies reported intracerebral hemorrhage (ICH) incidence and mortality as unchanged over time; however, comparisons between studies conducted in different health services obscure assessment of trends. We explored trends in ICH rates in a large, representative population in New South Wales, Australia’s most populous state (≈7.3 million).

Methods and Results—Adult hospitalizations with a principal ICH diagnosis from 2001 to 2009 were linked to death registrations through to June 30, 2010. Trends for overall, fatal, and nonfatal ICH rates within 30 days and fatal rates for 30-day survivors at 365 days were calculated. There were 11,332 ICH patient admissions meeting eligibility criteria, yielding a crude hospitalization rate of 25.2 per 100,000 (age-standardized rate: 17.2). Age- and sex-adjusted overall rates significantly declined by an average of 1.6% per year (P = 0.03). Fatal ICH declined by an average of 2.6% per year (P = 0.004). For 30-day survivors, a nonsignificant decline of 2.3% per year in fatal ICH at 365 days was estimated (P = 0.17). Male sex and birth in the Oceania region and Asia were associated with an increased ICH risk, although this depended on age. Approximately 12% of ICH admissions would be prevented if the socioeconomic circumstances of the population equated with those of the least disadvantaged.

Conclusions—Overall and fatal ICH rates have fallen in this large Australian population. Improvements in cardiovascular prevention and acute care may explain declining rates. There was no evidence of an increase in devastated survivors because the longer term mortality of 30-day survivors has not increased over time. (J Am Heart Assoc. 2014;3:e001161 doi: 10.1161/JAHA.114.001161)

Key Words: epidemiology • intracerebral hemorrhage • trends

Intracerebral hemorrhage (ICH) results in high case mortality and significant disability in survivors. Although ischemic stroke incidence appears to be declining, a recent systematic review of 36 epidemiological studies found no decrease in ICH incidence or mortality over time. Pooling epidemiological studies is problematic, given the heterogeneity of eligibility criteria, health services, and characteristics and risk factors of the underlying populations. One Australian population-based study reported declining ICH incidence based on 32, 22, and 19 ICH cases during 3 time periods from 1989 to 2001. Another epidemiological study from Oxfordshire, United Kingdom, reported declining ICH rates in a total of 107 cases across 2 time periods (1981–1986 and 2002–2006). The small numbers in these studies preclude definitive conclusions.

It has been suggested that hospitalization data sets may usefully monitor epidemiological trends in ICH. Resource-intensive methods for gold standard case ascertainment require identifying a small population base to ensure complete capture of cases typically yielding low numbers, which limit generalizability. Analysis of subgroups is also hampered. In contrast, as argued elsewhere, hospitalization administrative data sets yield very large numbers of cases that are prospectively and continuously accrued over several years and are representative of populations across a large geographic area. Hospital-based case selection has been shown to provide reliable data on ICH epidemiology when compared with a population-based gold standard registry. Using data linkage to identify individual patient admissions linked to mortality information offers a cost-effective opportunity to study patient-level trends of attack rates and fatality for ICH.

From the Ingham Institute of Applied Medical Research, Liverpool New South Wales, Australia (M.G., C.G., J.W.); School of Public Health and Community Medicine, The University of New South Wales, Sydney, Australia (M.G.); South Western Sydney Clinical School, The University of New South Wales, Liverpool, Australia (C.G., J.W.).

The results were accepted for presentation at the Stroke Society of Australasia’s Annual Scientific Meeting 2014.

Correspondence to: Melina Gattellari, PhD, Ingham Institute of Applied Medical Research, 1 Campbell Street, Liverpool, New South Wales 2170, Australia. E-mail: Melina.Gattellari@sswhs.nsw.gov.au

Received September 16, 2014; accepted October 28, 2014.

© 2014 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
that often is not possible with traditional epidemiological studies.

ICH management is evolving with emerging medical and neurosurgical interventions. Health services require estimates of the expected number of ICH cases and their outcomes to inform service delivery. Consequently, we undertook this analysis in a large population-based cohort to identify trends in ICH rates and fatality in Australia.

Methods

Cohort Selection

Hospital separations for patients aged ≥20 years with a principal diagnosis of ICH (International Classification of Diseases, 10th revision [ICD-10], code I61.x) from January 1, 2001, to December 31, 2009, within New South Wales (population ≈7.3 million) were selected from the Admitted Patient Data Collection, a census of all hospitals. According to coding standards, principal stroke diagnoses refer to acute admissions reflecting the main reason for the patient’s hospitalization. As a retrospective observational study using routinely collected hospitalization data, we could not prespecify the clinical and cerebral imaging criteria. These criteria are based on standardized coding by trained coders reviewing medical records including imaging to determine the main reason for the patient’s hospitalization. The coding criteria were that of nontraumatic stroke-like symptoms with imaging showing intracerebral hemorrhaging and a clinician-reported diagnosis of ICH. Administrative data are the basis for hospital remuneration and are subject to rigorous quality-assurance processes. Using gold standard methods for highly accurate linkage, separations were linked to create patient-level data and further linked to the state death registry through June 30, 2010, the most recently available information at the time of data extraction.

We excluded admissions due to improbable age (>105 years), admission prior to the study period, residence outside New South Wales, or likely misclassification of acute ICH indicated by early discharge within 48 hours or a concomitantly recorded diagnosis of traumatic head or stroke sequelae. We did not apply further exclusion criteria because our aim was to determine the burden of spontaneous ICH, regardless of cause, in this population. Secondary causes of ICH, such as arteriovenous malformations (AVMs) and cerebral neoplasms, were not excluded because their identification in the data set relies on recorded comorbidities, which tend to be underenumerated in routinely collected data. In addition, ascertainment of secondary causes of ICH such as AVMs and cerebral neoplasms using magnetic resonance imaging and angiograms instead of or in addition to more conventional and widely available computed tomography scanning may have varied across the health service and may have varied over time; therefore, exclusions may have biased results.

Statistical Analysis

Admission rates

We calculated crude admission rates per 100 000 person-years using population data for each year of our study period as denominators (http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/3201.0Jun%202009?OpenDocument). Age-standardized rates (ASRs) were directly standardized to the world population. We computed rates for fatal and nonfatal stroke at 30 days to provide respective measures of acute fatality or survival. Rates of fatal stroke at 365 days for 30-day survivors provided a measure of mortality in devastated survivors. Because 365-day follow-up was unavailable for admissions in the second half of 2009, fatal rates at 365 days for 30-day survivors for that year were adjusted using standard methods by dividing population estimates by 2.

Time trends in admission rates

The average annual percentage change was estimated to measure time trends in ICH rates using negative binomial regression models with the outcome equaling the number of ICH admissions, adjusting for age and sex and offset against the natural logarithm of the age- and sex-specific population. Overall trends in rates and trends by sex and age group were calculated. Interaction terms tested whether time trends varied according to sex, age, and year of admission and are reported as significant if the P value was <0.05.

All admissions were included in analyses including index (ie, the first occurrence of an event for a patient during the study period) and subsequent events arising in the same patient, consistent with standard epidemiological definitions of attack rates and previous research. The study of all admissions avoids bias in the assessment of time trends that would occur if we considered only index admissions, removing subsequent events that occurred for the same patient. Because index admissions would be more likely to appear in the earlier part of our study period, analysis of index admissions only would inflate the number of ICH admissions in the earlier years relative to the later years, biasing results toward a decreasing trend in admission rates.

Variability in admission rates

Negative binomial models calculating incidence rate ratios (IRR) determined variability in ICH rates according to age, sex, socioeconomic status (SES), and region of birth. For overall, fatal, and nonfatal ICH at 30 days, we tested all possible 2-way interaction terms among age, sex, year of birth, and SES, and region of birth.
admission, SES, and region of birth. A 3-way interaction term among age, sex, and year was also tested.

SES was defined using the Index of Relative Socio-Economic Disadvantage, a standardized measure of socio-economic deprivation based on location of residence within geographic confines known as local government areas. Key variables are used to assign scores denoting the relative concentration of disadvantage in these geographically defined areas. These variables include employment status, occupation, income, educational attainment, and ownership of assets. These data are collected from a government census of all Australian households and persons occupying nonprivate dwellings and are carried out once every 5 years. Participation is a legal requirement and approaches 100% (eg, 95.8% in the 2006 census; http://www.abs.gov.au/websitedbs/censushome.nsf/home/nonresponserates). Scores are conventionally ranked in ascending order and categorized using quintile cutoffs. Patient residence within local government areas is recorded in the Admitted Patient Data Collection, and these areas were assigned the corresponding quintile score for analysis. Region-of-birth groupings were assigned using a standard classification (http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/1269.0main+features102011).

**ICH risk factors by sex, age, SES, and region of birth**

To explore reasons for variability in ICH rates, we estimated the prevalence of ICH risk factors according to sex, age, region of birth, and SES. We determined the prevalence of the following risk factors, selecting both common and rarer causes of ICH: hypertension, diabetes, cerebral malignancies, smoking, alcohol or drug use, chronic kidney disease, anticoagulant use current at time of the hemorrhage, and AVMs and other venous malformations (ie, cerebral cavernous hemangioma). These risk factors were identified from secondary diagnoses in the hospital admission data set (up to 54 diagnoses in addition to the principal diagnosis are recorded) and 8 external cause-of-injury codes (enhancing ascertainment of smoking, drug and alcohol use, and current anticoagulant use) using ICD-10 coding (Table 1). Because comorbidities tend to be underascertained, we applied a look-back period identifying risk factors coded during the ICH admission and in any admission occurring in the 6 months prior to the patient’s ICH hospitalization to maximize ascertainment. Applying a look-back period maximizes ascertainment in Australian administrative data sets. Our selection of a 6-month look-back period was pragmatic because admissions are available to researchers only from July 1, 2000, providing 6 months of clearance for all patients admitted with ICH from 2001 onward. A look-back period was not applied when identifying anticoagulant use because we wished to determine anticoagulant use current at the time of the ICH. We also applied procedure codes for chronic kidney disease to capture patients receiving renal dialysis. These procedure codes are based on the Australian government’s Medicare Benefits Schedule coding that hospital coders apply to all diagnostic and treatment procedures listed on the schedule to ensure financial reimbursement. Procedure coding is defined according to the standardized Australian Classification of Health Interventions, and procedures are coded with a high level of accuracy. Mean and median ages were calculated for sex, SES, and region of birth.

**Table 1. ICD-10 Diagnostic and Procedure Codes Applied to Ascertaining Intracerebral Hemorrhage Risk Factors**

| Risk Factor                                      | ICD-10 Codes                                  |
|-------------------------------------------------|-----------------------------------------------|
| Diabetes                                        | E10 to E14                                    |
| Hypertension                                    | I10 to I14                                    |
| Cerebral malignancies (primary or metastatic)    | C70.x, C71.x, C79.3                           |
| Smoking                                         | F17, Z72.0, Z71.6, Z86.43                     |
| Alcohol or drug use                             | E52, F10, K70, X45, X65, Y15, Y90, Y91, E24.4, E51.2, G31.2, G62.1, G72.1, I42.6, K29.2, K86.0,035.4, P04.3, Q86.0, R78.0, T50.6, T51.0, T51.1, T51.9, Y57.3, Z50.2,Z71.4,Z72.1,Z78.1, F11,F12,F13,F14,F15,F16,F18, F19,T40,X42,T43.6,Z50.3 |
| Arteriovenous malformations/other malformations  | Q28.2, D18, I00.8                             |
| Chronic kidney disease                          | ICD-10 diagnosis codes: N00 to N08, I12, I13,N11, N12, N14, N15, N16, N18, N19, N25, N26, N27, N28, O60, O61, O62, O63, Z49, E10.2, E11.2, E12.2,E14.2, E39.1, N39.2, I15.0, I15.1, T82.4, T86.1, Z94.0, Z99.2; ICD-10 Procedure codes: 36561-00, 36503-00, 36503-01, 13100-06, 13100-07, 13100-08, 13100-00 |
| Anticoagulant use                                | D68.3, T45.5, Y44.2, Z92.1                    |

ICD-10 indicates International Classification of Diseases, 10th revision.
**Ethics approval**

The New South Wales Population and Health Services research ethics committee and the University of New South Wales approved analyses of ICH data as part of the Program of Research Informing Stroke Management (PRISM) study.

**Results**

**Patient Selection and Characteristics**

There were 12,304 acute admissions with a principal diagnosis of ICH identified prior to applying exclusion criteria. Overall, 7.9% of admissions were excluded because of improbable age (n=1), admission prior to 2001 (n=1), residence outside New South Wales (n=277), or likely misclassification indicated by early discharge within 48 hours (n=240) or a concomitantly recorded diagnosis of traumatic injury (n=264) or stroke sequelae (n=189), leaving 11,332 eligible admissions. Of those, 49.8% were female, with a median age of 79 years (IQR 69 to 85). Male patients were significantly younger (median age 73 years, IQR 62 to 80) (P<0.001). More than two thirds were born in Australia (68.3%; n=7527).

**Time Trends in Overall Admission Rates**

The crude admission rate was 25.2 per 100,000 and 17.2 when age standardized against the world population (Table 2). ASRs for men and women were 20.0 and 14.5, respectively. Age- and sex-adjusted admission rates declined during the study period by an average of 1.6% per year (P=0.03) (Figure 1, Table 3). Nonsignificant interaction terms indicated that the decline in rates did not differ significantly by sex or age, although declines were noted in all age groups except those aged >90 years (Table 2).

**Trends in Fatal and Nonfatal ICH Rates**

By 30 days, 4246 (37.5%) of ICH admissions resulted in death. Fatal ICH occurred in 9.4 patients per 100,000 population (ASR 5.9 per 100,000). The nonfatal stroke rate was 15.8 per 100,000 or 11.2 per 100,000 when standardized to the World Health Organization-reported world population.12 The average annual percentage decline in fatal ICH rates was 2.6% per year (P=0.004), and the decline was similar for men and women (Pinteraction=0.57). Fatal rates declined for all ages except those aged >90 years; however, there was no significant variability in declining fatal ICH rates due to age (Pinteraction=0.60) (Table 3). The 1% average percentage decline in nonfatal ICH rates was not significant (P=0.19).

The overall fatal ICH rate within 365 days for 30-day survivors was estimated as 2.7 per 100,000 (ASR 1.7, 95% CI 1.6 to 1.8) and declined by an average of 2.3% per year (95% CI –5.5 to 1.0); this decline was not significant (P=0.17).

**Variability in ICH Admission Rates**

**Age and sex**

Admission rates were significantly elevated in men and in relatively older patients (P<0.001 for both) (Table 2). Crude rates did not differ between the sexes (Table 2); however, age-
and year-adjusted ICH rates were 26% lower for women than for men (IRR 0.74, 95% CI 0.69 to 0.80). Male sex and increasing age were also associated with higher adjusted rates of both fatal and nonfatal ICH rates (P < 0.001 for both) (Tables 4 and 5).

Rates of ICH and fatal ICH were higher in men than in women in those aged 40 to 89 years and similar in those aged <40 years and >90 years (P interaction < 0.001 and P interaction = 0.003, respectively). Nonfatal ICH rates were similar for men and women aged >80 years (P interaction = 0.003) (Tables 2, 4, and 5).

Older age and male sex were also associated with higher rates of fatal ICH by 365 days in those who survived the first 30-days after their ICH.

**SES**

Patients residing in the least disadvantaged areas were 27% less likely to be admitted to the hospital with an ICH than those residing in areas of greatest socioeconomic disadvantage (Figure 2, Table 6). This relationship also held for fatal and nonfatal ICH (Tables 6 and 7). Significant interactions between SES and age revealed that these associations applied to patients aged <80 years (Table 8). SES was not associated with ICH fatality at 365 days for 30-day survivors.

ICH risk attributable to SES was 20.1%; 1 in 5 ICH admissions occurring in areas of greatest socioeconomic disadvantage can be attributed to socioeconomic deprivation. Slightly >1 in 9 ICH admissions (11.9%) in the total population would be avoided if the risk of ICH for all residents equaled that of the most affluent (Table 9).

**Region of birth**

Compared with people born in Australia, those born in the Oceania region or in Northeast or Southeast Asia were between 44% and 68% more likely to be admitted to the hospital with ICH and between 16% and 44% more likely to die from ICH within 30 days (Tables 6 and 10). People born in Europe were at a reduced risk of ICH and of dying from it. Residents born in the Middle East and North Africa were 10%
more likely to experience an ICH compared with Australia-born residents, although confidence limits for the estimated effect included the null value. Differences related to region of birth depended on age ($P_{interaction}=0.02$) (Table 11). People born in the Oceania region had particularly elevated ASRs of ICH in those aged <65 years. The elevated ICH risk in Northeast Asia–born residents was evident only in those aged >45 years, whereas residents from Southeast Asia had an elevated risk regardless of age.

Among 30-day survivors, ICH fatality rates at 365 days for those born in the Oceania region, Northeast Asia, and the Middle East were between 23% and 89% higher than the rate for Australia-born residents (Table 6).

### Table 4. ASR per 100 000 of Fatal Intracerebral Hemorrhage in New South Wales in 2001–2009 by Sex and Age

| Year | ASR, WHO World Population (95% CI) |
|------|-----------------------------------|
| **Men** | |
| 20 to 29 | * |
| 30 to 39 | 0.5 (0.3 to 0.7) |
| 40 to 49 | 1.7 (1.4 to 2.1) |
| 50 to 59 | 3.5 (3.0 to 4.2) |
| 60 to 69 | 12.2 (10.9 to 13.5) |
| 70 to 79 | 37.8 (34.9 to 40.7) |
| 80 to 89 | 95.8 (88.8 to 103.1) |
| ≥90 | 127.2 (104.2 to 152.4) |
| **Women** | |
| 20 to 29 | * |
| 30 to 39 | 0.4 (0.2 to 0.6) |
| 40 to 49 | 0.8 (0.5 to 1.1) |
| 50 to 59 | 2.5 (2.0 to 3.0) |
| 60 to 69 | 6.9 (5.9 to 7.9) |
| 70 to 79 | 28.7 (26.4 to 31.1) |
| 80 to 89 | 82.0 (76.9 to 87.3) |
| ≥90 | 135.7 (121.2 to 151.0) |
| **Both sexes** | |
| 20 to 29 | * |
| 30 to 39 | 0.5 (0.3 to 0.6) |
| 40 to 49 | 1.2 (1.0 to 1.5) |
| 50 to 59 | 3.0 (2.6 to 3.4) |
| 60 to 69 | 9.5 (8.7 to 10.4) |
| 70 to 79 | 32.9 (31.1 to 34.8) |
| 80 to 89 | 87.4 (83.3 to 91.7) |
| ≥90 | 133.3 (120.9 to 146.2) |

ASR indicates age-standardized rate; WHO, World Health Organization. *Cells sizes and calculations based on sample sizes ≤10 or cells that can be used to deduce cells with ≤10 patients have been suppressed to protect patient privacy in accordance with local standards.

### Table 5. ASR per 100 000 of Nonfatal Intracerebral Hemorrhage in New South Wales in 2001–2009 by Sex and Age

| Year | ASR, WHO World Population (95% CI) |
|------|-----------------------------------|
| **Men** | |
| 20 to 29 | * |
| 30 to 39 | 2.3 (1.9 to 2.8) |
| 40 to 49 | 5.9 (5.2 to 6.7) |
| 50 to 59 | 13.3 (12.1 to 14.5) |
| 60 to 69 | 30.3 (28.2 to 32.5) |
| 70 to 79 | 64.2 (60.5 to 68.1) |
| 80 to 89 | 103.0 (95.8 to 110.6) |
| ≥90 | 106.5 (85.9 to 129.2) |
| **Women** | |
| 20 to 29 | * |
| 30 to 39 | 1.8 (1.4 to 2.2) |
| 40 to 49 | 4.1 (3.5 to 4.7) |
| 50 to 59 | 7.6 (6.8 to 8.5) |
| 60 to 69 | 18.6 (17.0 to 20.3) |
| 70 to 79 | 45.9 (43.0 to 48.9) |
| 80 to 89 | 97.0 (91.5 to 102.8) |
| ≥90 | 101.2 (88.8 to 114.5) |
| **Both sexes** | |
| 20 to 29 | * |
| 30 to 39 | 2.0 (1.8 to 2.4) |
| 40 to 49 | 5.0 (4.6 to 5.5) |
| 50 to 59 | 10.5 (9.7 to 11.2) |
| 60 to 69 | 24.4 (23.1 to 25.7) |
| 70 to 79 | 54.4 (52.1 to 56.8) |
| 80 to 89 | 99.6 (95.2 to 104.2) |
| ≥90 | 102.9 (92.1 to 114.2) |

ASR indicates age-standardized rate; WHO, World Health Organization. *Cells sizes and calculations based on sample sizes ≤10 or cells that can be used to deduce cells with ≤10 patients have been suppressed to protect patient privacy in accordance with local standards.

### ICH risk factors

Age of ICH onset was significantly lower in men; in those residing in the most disadvantaged areas; and for those born in Oceania, North Africa or the Middle East, and in Northeast and Southeast Asia (Table 12). With the exception of hypertension, all other assessed risk factors were more prevalent in men than in women, including AVMs, cerebral malignancies, and drug and alcohol use. AVMs were present in 19.2% of ICH patients aged <40 years and in 8.6% aged 40 to 49 years. Cerebral malignancies and alcohol and drug use
Figure 2. ASRs for intracerebral hemorrhage according to the ISRD measuring SES. 1 = low SES; 5 = high SES. ASR indicates age-standardized rate; ICH, intracerebral hemorrhage; ISRD, Index of Relative Socio-Economic Disadvantage; SES, socioeconomic status.

Table 6. IRR* in New South Wales in 2001–2009 According to Sex, Age, SES, and Region of Birth

| SES (IRSD)† | ICH Admission Rate IRR (95% CI) | Fatal ICH 30-Day IRR (95% CI) | Nonfatal ICH 30-Day IRR (95% CI) | Fatal ICH at 365 Days IRR (95% CI)‡ |
|-------------|---------------------------------|-------------------------------|-------------------------------|-------------------------------------|
| Quintile 1  | Referent§                        | Referent§                     | Referent§                     | Referent§                           |
| Quintile 2  | 0.91 (0.80 to 1.05)              | 0.94 (0.77 to 1.14)           | 0.89 (0.77 to 1.04)           | 1.04 (0.76 to 1.41)                 |
| Quintile 3  | 0.89 (0.78 to 1.01)              | 0.94 (0.78 to 1.12)           | 0.87 (0.77 to 1.00)           | 0.88 (0.66 to 1.17)                 |
| Quintile 4  | 0.91 (0.80 to 1.03)              | 0.93 (0.78 to 1.11)           | 0.90 (0.79 to 1.03)           | 0.90 (0.68 to 1.20)                 |
| Quintile 5  | 0.73 (0.64 to 0.83)              | 0.76 (0.64 to 0.91)           | 0.74 (0.65 to 0.85)           | 0.80 (0.60 to 1.06)                 |

Region of birth

| Australia   | Referent§                        | Referent§                     | Referent§                     | Referent§                           |
|-------------|---------------------------------|-------------------------------|-------------------------------|-------------------------------------|
| Other Oceania | 1.52 (1.31 to 1.77)          | 1.16 (0.91 to 1.48)           | 1.69 (1.44 to 2.00)           | 1.89 (1.30 to 2.74)                 |
| Northwest Europe | 0.73 (0.65 to 0.82)        | 0.65 (0.56 to 0.76)           | 0.80 (0.70 to 0.90)           | 0.88 (0.69 to 1.12)                 |
| Southeast Europe | 0.93 (0.83 to 1.04)        | 0.86 (0.74 to 0.99)           | 0.98 (0.87 to 1.11)           | 0.87 (0.68 to 1.11)                 |
| North Africa/Middle East | 1.10 (0.95 to 1.29)   | 0.99 (0.78 to 1.25)           | 1.17 (0.98 to 1.40)           | 1.23 (0.82 to 1.84)                 |
| Other Africa | 0.95 (0.73 to 1.23)           | 0.94 (0.62 to 1.43)           | 0.96 (0.71 to 1.32)           | 0.93 (0.41 to 2.10)                 |
| Southeast Asia | 1.68 (1.47 to 1.91)       | 1.44 (1.17 to 1.77)           | 1.79 (1.54 to 2.08)           | 0.92 (0.58 to 1.48)                 |
| Northeast Asia | 1.44 (1.26 to 1.65)       | 1.36 (1.12 to 1.65)           | 1.50 (1.29 to 1.75)           | 1.33 (0.92 to 1.91)                 |
| Other Asia   | 0.80 (0.64 to 1.01)           | 0.75 (0.51 to 1.10)           | 0.83 (0.63 to 1.10)           | 0.30 (0.10 to 0.94)                 |
| Americas     | 0.95 (0.77 to 1.18)           | 0.64 (0.42 to 0.97)           | 1.13 (0.88 to 1.44)           | 0.53 (0.22 to 1.29)                 |

ICH indicates intracerebral hemorrhage; IRR, incident rate ratio; IRSD, Index of Relative Socio-Economic Disadvantage; SES, socioeconomic status.

*Adjusting for age, sex, and year. IRRs can be interpreted as relative risks whereby ratios below the null value of 1 indicate a reduced risk when compared with the referent group, whereas ratios >1 indicate an increased risk relative to the referent group.

†Estimated in 30-day survivors.

‡All residential areas in New South Wales are assigned a score according to standard methods and scores are ranked according to quintiles. Patient residence within local government areas were recorded in the data set, and these geographic areas were assigned the corresponding quintile ranking. Lower quintile rankings indicate residence in geographic areas of greater relative socioeconomic disadvantage or deprivation and therefore lower SES.

#P<0.001.

|     | 1  | 2  | 3  | 4  | 5  |
|-----|----|----|----|----|----|
| 12  | 14 | 16 | 18 | 20 | 22 |
| ASR per 100,000 | ISRD quintile ranking | 1 = low SES; 5 = high SES. ASR indicates age-standardized rate; ICH, intracerebral hemorrhage; ISRD, Index of Relative Socio-Economic Disadvantage; SES, socioeconomic status.
were also more prevalent in patients aged <50 years (20% and 5%, respectively). Anticoagulant use was most prevalent in patients aged between 50 and 79 years. Among patients born in regions with the highest ICH rates, diabetes, renal disease, and hypertension were more prevalent in Asia-born patients and those born in the Middle East or North Africa and Oceania. AVMs were more frequently found in patients of Southeast Asian origin (3.4%).

Discussion

PRISM Study: Declining ICH Rates

This is the first large-scale study of ICH epidemiology in Australia, and it reports falling rates of hospital admission and fatal ICH in an unselected population of >7.3 million and 11,332 ICH patients. There has been little evidence internationally of reductions in ICH attack rates including fatal ICH.1 The large number of ICH admissions identified over a 9-year period within the same geographically defined area is a major strength of the study.

An analysis pooling ICH cases from 36 international epidemiological studies published between 1980 and 20082 demonstrated declining incidence or mortality.1 One recent study of 441 ICH patients reported no overall decline in first-ever ICH rates in Dijon, France, over 3 time periods from 1985 to 200822 but reported increasing rates in people aged >75 years, decreasing rates in those aged <60 years, and stable rates for the population aged 60 to 74 years. The

Table 7. ASR per 100,000 of Overall, Fatal, and Nonfatal ICH by SES

| IRSD Quintile* | ICH Cases | Crude Rate | ASR WHO World Population 95% CI |
|----------------|-----------|------------|---------------------------------|
| Overall ICH (ie, admissions) | | | |
| Quintile 1 (low SES) | 1358 | 27.8 | 19.3 | 18.3 to 20.4 |
| Quintile 2 | 1194 | 26.9 | 17.6 | 16.6 to 18.7 |
| Quintile 3 | 2914 | 25.9 | 17.3 | 16.6 to 17.9 |
| Quintile 4 | 2792 | 24.9 | 17.5 | 16.8 to 18.2 |
| Quintile 5 (high SES) | 2962 | 22.2 | 14.8 | 14.2 to 15.3 |
| Fatal ICH (30 days) | | | |
| Quintile 1 (low SES) | 489 | 10.0 | 6.5 | 5.9 to 7.1 |
| Quintile 2 | 450 | 10.1 | 6.1 | 5.6 to 6.7 |
| Quintile 3 | 1093 | 9.7 | 6.0 | 5.6 to 6.4 |
| Quintile 4 | 1069 | 9.5 | 6.1 | 5.8 to 6.5 |
| Quintile 5 (high SES) | 1144 | 8.6 | 5.2 | 4.9 to 5.5 |
| Nonfatal ICH (30 days) | | | |
| Quintile 1 (low SES) | 869 | 17.8 | 12.8 | 12.0 to 13.7 |
| Quintile 2 | 744 | 16.8 | 11.5 | 10.6 to 12.3 |
| Quintile 3 | 1821 | 16.2 | 11.3 | 10.7 to 11.8 |
| Quintile 4 | 1723 | 15.4 | 11.4 | 10.8 to 11.9 |
| Quintile 5 (high SES) | 1818 | 13.6 | 9.6 | 9.1 to 10.1 |
| Fatal ICH 365 days in 30-day survivors | | | |
| Quintile 1 (low SES) | 128 | 2.8 | 1.9 | 1.5 to 2.2 |
| Quintile 2 | 130 | 3.1 | 1.9 | 1.6 to 2.3 |
| Quintile 3 | 277 | 2.6 | 1.6 | 1.4 to 1.8 |
| Quintile 4 | 281 | 2.7 | 1.6 | 1.4 to 1.8 |
| Quintile 5 (high SES) | 312 | 2.5 | 1.5 | 1.3 to 1.6 |

ICH indicates intracerebral hemorrhage; IRR, incident rate ratio; IRSD, Index of Relative Socio-Economic Disadvantage; SES, socioeconomic status; WHO, World Health Organization.

Table 8. Crude and Age-Standardised Overall ICH Rates per 100,000 for SES by Age in New South Wales (2001–2009)*

| SES Quintile | ICH Cases | Crude Rate | ASR WHO World Population 95% CI |
|---------------|-----------|------------|---------------------------------|
| Aged 20 to 39 years | | | |
| Quintile 1 (low SES) | 40 | 2.2 | 2.2 | 1.5 to 2.9 |
| Quintile 2 | 49 | 3.2 | 3.1 | 2.3 to 4.0 |
| Quintile 3 | 89 | 2.1 | 2.0 | 1.6 to 2.5 |
| Quintile 4 | 97 | 2.1 | 2.1 | 1.7 to 2.5 |
| Quintile 5 (high SES) | 61 | 1.2 | 1.1 | 0.8 to 1.4 |
| Aged 40 to 59 years | | | |
| Quintile 1 (low SES) | 229 | 12.5 | 12.3 | 10.7 to 13.9 |
| Quintile 2 | 179 | 10.7 | 10.5 | 9.0 to 12.1 |
| Quintile 3 | 396 | 9.7 | 9.4 | 8.5 to 10.4 |
| Quintile 4 | 393 | 10 | 9.8 | 8.9 to 10.8 |
| Quintile 5 (high SES) | 360 | 7.3 | 7.2 | 6.5 to 8.0 |
| Aged 60 to 79 years | | | |
| Quintile 1 (low SES) | 665 | 64.6 | 60.1 | 55.6 to 64.8 |
| Quintile 2 | 557 | 56.2 | 52.1 | 47.8 to 56.5 |
| Quintile 3 | 1460 | 60.8 | 56.6 | 53.7 to 59.6 |
| Quintile 4 | 1181 | 56.2 | 52.4 | 49.4 to 55.5 |
| Quintile 5 (high SES) | 1179 | 48 | 44.7 | 42.2 to 47.3 |
| Aged ≥80 years | | | |
| Quintile 1 (low SES) | 424 | 190.7 | 190.5 | 172.8 to 209.1 |
| Quintile 2 | 409 | 180.0 | 179.7 | 162.7 to 197.6 |
| Quintile 3 | 969 | 172.6 | 171.3 | 160.7 to 182.3 |
| Quintile 4 | 1121 | 206.4 | 203.8 | 192.0 to 216.0 |
| Quintile 5 (high SES) | 1362 | 202.4 | 197.5 | 187.1 to 208.2 |

ASR indicates age-standardized rate; ICH, intracerebral hemorrhage; SES, socioeconomic status; WHO, World Health Organization.

*Excludes 112 patients with missing data.

ICH indicates intracerebral hemorrhage; IRR, incident rate ratio; IRSD, Index of Relative Socio-Economic Disadvantage; SES, socioeconomic status; WHO, World Health Organization.

*To Minimize Small Cell Sizes, Age Categories were Collapsed to 20-Year Age Groups When Testing the Interaction Between Age and Relative Socio-Economic Disadvantage.
Table 9. Calculation of Attributable Risk Percent and Population Attributable Risk Percentage

| IRSD Level                  | Calculation                  | Attributable Risk Percentage |
|-----------------------------|------------------------------|------------------------------|
| Quintile 1 (Low SES)        | [(27.8 – 22.2)/27.8] x 100  | 20.1                         |
| Quintile 2                  | [(26.9 – 22.2)/26.9] x 100  | 17.5                         |
| Quintile 3                  | [(25.9 – 22.2)/25.9] x 100  | 14.3                         |
| Quintile 4                  | [(24.9 – 22.2)/25.9] x 100  | 10.8                         |

Attributable risk percent: We calculated the attributable risk percent to determine the excess of ICH risk in people residing in areas of greatest socioeconomic disadvantage that can be attributed to socioeconomic deprivation. We applied the following formula, using crude rates: \[ \text{PAR} = \left( \frac{\text{Ir} - \text{Ie}}{\text{Ie}} \right) \times 100 \] where \( \text{Ir} \) is incidence in exposed per 100 000 and \( \text{Ie} \) is incidence in non-exposed.\(^3\) We used crude rates for overall ICH (ie, admission rates). Those residing in the least disadvantaged areas were considered nonexposed to socioeconomic deprivation (IRSD quintile 5). Consequently, the attributable risk percent for each of the 4 quintile levels of SES indicating greater relative socioeconomic disadvantage than the least disadvantaged group (ie, the nonexposed group) is as described in the table. PAR percent: We calculated the population attributable risk to determine the excess rate of ICH in the population that can be attributed to socioeconomic deprivation. We applied the following formula, using crude ICH overall/admission rates: \[ \text{PAR\%} = \left( \frac{\text{ Ir } - \text{ Ie } }{ \text{ Ie } } \right) \times 100 \] where \( \text{Ir} \) is incidence of overall ICH in the population, \( \text{Ie} \) is incidence of overall ICH in the nonexposed group (ie, incidence for the population residing in the least socioeconomic disadvantaged areas [IRSD quintile 5]). Consequently, PAR\%: \[ \left( \frac{\text{Ir} - \text{Ie}}{\text{Ie}} \right) \times 100 = 11.9\%. \] Moreover, 22.2 per 100 000 is the crude overall ICH rate for people residing in the area of the least socioeconomic disadvantage (ie, the highest SES group or quintile 5). ICH indicates intracerebral hemorrhage; IRSD, Index of Relative Socio-Economic Disadvantage; PAR, population attributable risk; SES, socioeconomic status.

The authors did not assess effect modification by age, and that may limit the conclusions that can be drawn. In contrast, we found declining rates of overall and fatal ICH that were not modified by age. Another gold standard epidemiological study carried out in Texas demonstrated a 31% decrease in hospitalized ICH incidence from 2000 to 2010 in 734 ICH cases, with no decline in case fatality noted.\(^23\) Declines in ICH incidence were seen in all ages except those aged 40 to 49 years, although effect modification by age was not formally tested. In Australia, stroke rates have been declining,\(^2,24,25\) although only 1 study noted time trends in ICH, reporting decreasing incidence and case fatality based on 73 ICH cases accrued over 3 discrete time periods, the latest in 2001.\(^2\) Research from Oxfordshire has reported declining ICH incidence based on 107 patients recruited between 2 time periods (1981–1986 and 2002–2006).\(^3\) To our knowledge, studies using administrative data have not reported declining ICH attack rates.\(^26–32\) Two studies reported declines in 1 of several subgroups examined, specifically, women aged 35 to 44 years,\(^31\) and in men and women aged 55 to 64 years\(^27\) without formally assessing effect modification. Data linkage has not been widely used.\(^28\)

Improved risk management, particularly of hypertension, may explain declines in ICH admissions. In Australia, the proportion of adults in the community with high blood pressure has declined significantly over time.\(^33\) Approximately 6% and 13% of ICH can be attributed to hazardous alcohol intake and a history of ischemic stroke, respectively.\(^34\) and decreasing rates of both in Australia\(^2,35\) may have translated into reduced ICH risk. Smoking prevalence has also decreased in our population during the study period,\(^35\) although its etiological role in ICH remains uncertain.\(^36\) Improvements in hypertension control in the community may also explain reductions in ICH mortality, given that prestroke antihypertensive therapy lowers overall stroke mortality.\(^37\)

Two key evidence-based health service strategies implemented during the study period may have affected ICH outcomes. One strategy was the coordinated implementation of New South Wales metropolitan stroke units, which commenced with 22 units from 2003 and expanded throughout the study period.\(^38\) Stroke units are an innovation associated with reduced death and disability in ICH.\(^39\) Another statewide network of 10 coordinated neurosurgical units was implemented. These units are colocated with tertiary intensive care and trauma services and facilitate access to these specialized services, including highly resourced and experienced neurosurgical teams that are now routinely involved in emergency ICH management. Neurosurgical care and intensive care are recommended for ICH management, although it seems difficult to show a benefit of specific treatments.\(^8\) Transferring patients to specialist centers may reduce mortality because outcomes for patients undergoing neurosurgery are better in hospitals with higher ICH case loads.\(^40\)

For 30-day survivors, we report a nonsignificant decline in 365-day mortality over time, suggesting that advances in acute care have not resulted in a concomitant increase in the number of devastated survivors whose deaths due to complications are delayed beyond the acute period. The nonsignificant decline suggests more could be done during the postacute period, including secondary prevention.

**Burden of ICH in Australia**

We report a crude hospitalization attack rate of 25.2 per 100 000 and a fatal attack rate within 30 days of 9.4 per 100 000 in an adult population. Our age-standardized attack rate was 17 per 100 000. The rates reported in this paper include both incident and recurrent hospitalized ICH admissions in adults aged ≥20 years. Direct comparisons between this estimate and other studies are difficult because studies vary in their case definition and ascertainment, the age groups represented (ie, adult ages versus all age groups), whether or not only ICH cases were included as the first-ever stroke, and the selection of the standard population. We also note that the cohort under study in this paper includes all nontraumatic, spontaneous causes of ICH to permit an assessment of the burden of ICH in our community. Although this approach is consistent with several previous epidemiological studies,\(^1,23\)

DOI: 10.1161/JAHA.114.001161
other researchers have elected to remove some secondary causes of ICH such as AVMs\textsuperscript{1} and/or malignancies.\textsuperscript{1,23} By definition, gold standard epidemiological studies usually,\textsuperscript{1} but not always, include out-of-hospital events,\textsuperscript{23} whereas our study included hospitalizations to determine the burden of ICH in our statewide health service. Worldwide rates of incident ICH vary significantly from 1.8 to 129.6 per 100 000. Van Asch et al\textsuperscript{1} pooled ICH crude incidence rates and reported a worldwide pooled rate of 25.6 per 100 000 and 24.2 per 100 000 in white populations, broadly corresponding to our estimated crude attack rate of hospitalized ICH of 25.2 per 100 000.

The burden of ICH is unequally distributed in this large Australian community. As expected, increasing age was associated with an increasing risk of ICH,\textsuperscript{1} whereas male sex conferred a higher risk of ICH hospitalization and of fatal and nonfatal ICH. ICH risk factors were more prevalent in male patients, corroborating the association between sex and ICH. ICH risk in men and women was equivalent in adults aged <40 years and in the very elderly. Male sex has been associated with increasing ICH risk in Australia,\textsuperscript{2,41} a finding that is not universal.\textsuperscript{1} Other studies have also reported varying patterns of stroke risk by sex according to age, but effect modification is rarely assessed.\textsuperscript{27,31,42} Nonmodifiable risk factors, such as aneurysms; cavernous angiomas; hypercholesterolemia; hematological cancers; coagulopathies; and, in women, pregnancy-related complications such as pre-eclampsia may have attenuated the heightened risk in men and in the relatively young,\textsuperscript{43} whereas cerebral amyloid angiopathy, which affects men and women equally, assumes greater importance with age.\textsuperscript{44} As observed elsewhere,\textsuperscript{42} sex differences in stroke risk among the elderly may be partly explained by using an open-ended age category because women are more likely to realize stroke risk during their increased life span.

The Australian population comprises a large proportion of people born overseas (≈33% in this study), affording a unique opportunity to examine disparities in ICH risk based on region.

### Table 10. Region of Birth and Risk of Overall ICH and Fatal and Nonfatal ICH

| Region of Birth | ICH Cases | Crude Rate | ASR | 95% CI |
|-----------------|-----------|------------|-----|--------|
| **Overall ICH admission rates** |           |            |     |        |
| Australia       | 7491      | 30.8       | 21.8| 21.3 to 22.3 |
| Other Oceania   | 275       | 24.9       | 31.1| 27.5 to 35.0 |
| Northwest Europe| 962       | 31.4       | 16.3| 15.3 to 17.5 |
| Southeast Europe| 983       | 46.8       | 20.9| 19.4 to 22.5 |
| North Africa/Middle East | 257       | 25.0       | 24.8| 21.8 to 27.9 |
| Other Africa    | *         | *          | *   | *      |
| Southeast Asia  | 378       | 25.2       | 35.4| 31.8 to 39.2 |
| Northeast Asia  | 382       | 29.1       | 31.8| 28.7 to 35.1 |
| Other Asia      | *         | *          | *   | *      |
| Americas        | *         | *          | *   | *      |
| **Fatal ICH (30 days)** |           |            |     |        |
| Australia       | 2933      | 12.1       | 8.0 | 7.7 to 8.3 |
| Other Oceania   | 73        | 6.6        | 8.7 | 6.7 to 10.8 |
| Northwest Europe| 333       | 10.9       | 5.2 | 4.6 to 5.8 |
| Southeast Europe| 363       | 17.3       | 6.7 | 6.0 to 7.5 |
| North Africa/Middle East | 82       | 8.0        | 8.0 | 6.3 to 9.8 |
| Other Africa    | *         | *          | *   | *      |
| Southeast Asia  | 112       | 7.5        | 11.2| 9.2 to 13.4 |
| Northeast Asia  | 131       | 10.0       | 10.9| 9.1 to 12.8 |
| Other Asia      | *         | *          | *   | *      |
| Americas        | *         | *          | *   | *      |
| **Nonfatal ICH (30 days)** |           |            |     |        |
| Australia       | 4558      | 18.7       | 13.8| 13.4 to 14.3 |
| Other Oceania   | 202       | 18.3       | 22.5| 19.4 to 25.7 |
| Northwest Europe| 629       | 20.6       | 11.2| 10.2 to 12.1 |
| Southeast Europe| 620       | 29.5       | 14.2| 12.9 to 15.6 |
| North Africa/Middle East | 175       | 17.0       | 16.8| 14.4 to 19.4 |
| Other Africa    | *         | *          | *   | *      |
| Southeast Asia  | 266       | 17.7       | 24.2| 21.3 to 27.3 |
| Northeast Asia  | 251       | 19.1       | 20.9| 18.4 to 23.6 |
| Other Asia      | *         | *          | *   | *      |
| Americas        | *         | *          | *   | *      |
| **Fatal ICH (365 days in 30 day survivors)** |           |            |     |        |
| Australia       | 763       | 3.3        | 2.2 | 2.0 to 2.4 |
| Other Oceania   | 32        | 3.1        | 4.2 | 2.9 to 5.8 |
| Northwest Europe| 121       | 4.2        | 1.9 | 1.6 to 2.3 |
| Southeast Europe| 95        | 4.8        | 2.1 | 1.6 to 2.6 |
| North Africa/Middle East | 27       | 2.8        | 2.8 | 1.8 to 3.9 |

ASR indicates age-standardized rate; ICH, intracerebral hemorrhage.

*Cells based on sample sizes ≤10 or cells that can be used to deduce cells with ≤10 patients have been suppressed to protect patient privacy in accordance with local standards.

---

DOI: 10.1161/JAHA.114.001161

Journal of the American Heart Association
of birth within the same geographically defined area and time frame. Stroke risk associated with country of birth has been explored in Australia, but that analysis excluded ICH. Our analysis represented 10 regions and overcame limitations of comparing rates from different countries, for which differences in health service delivery, case selection, and time period under study may have confounded observed geographic variations. Using administrative data, we report that risks are elevated for patients born in Northeast and Southeast Asia but not in other Asian regions. Elevated incidence in Pacific Islander and Asian populations has been reported in Auckland, New Zealand, using gold standard epidemiological methods. Residents born in the Middle East or North Africa also experienced an increased risk of nonfatal ICH; few studies have explored ICH risk in these populations. In all cases, these patients experienced ICH at younger ages than Australia-born residents, exacerbating the burden of disease in these communities. Evidence from this study and others suggests that the increased prevalence of hypertension, renal disease, and diabetes likely underpins the increased risk seen in these groups. Significant effect modification between region of birth and age is a novel finding suggesting different etiological influences. The risk associated with being born in the Oceania region appeared stronger in those aged <65 years, whereas the increased risk of ICH seen in people of Northeast Asian origin was evident only in those aged >45 years. Southeast Asia-born members of the community were at a similarly elevated risk throughout adulthood, with our results suggesting that AVMs are an important etiological risk factor.

Approximately 12% of ICH admissions in this population could have been prevented if the socioeconomic circumstances of the population were equal with those of the least disadvantaged in the Australian population. The relationship between SES and stroke risk has been reported previously, although results appear more consistent for ischemic rather

### Table 11. Crude and Age-Standardised Overall Intracerebral Hemorrhage Rates per 100 000 for Region of Birth by Age in New South Wales (2001–2009)*

| Region of Birth       | ASR, WHO World Population (95% CI) |
|-----------------------|-------------------------------------|
| **Aged 25 to 44 years** |                                     |
| Australia             | 3.3 (2.9 to 3.6)                    |
| Other Oceania         | 5.6 (3.9 to 7.6)                    |
| Northwest Europe      | 1.6 (0.8 to 2.5)                    |
| Southeast Europe      | 2.9 (1.5 to 4.8)                    |
| North Africa/Middle East | 2.5 (1.3 to 4.1)                  |
| Other Africa          |                                     |
| Southeast Asia        | 4.8 (3.4 to 6.4)                    |
| Northeast Asia        | 2.6 (1.5 to 3.9)                    |
| Other Asia            |                                     |
| Americas              |                                     |
| **Aged 45 to 64 years** |                                     |
| Australia             | 14.6 (13.8 to 15.4)                 |
| Other Oceania         | 31.0 (25.5 to 37.0)                 |
| Northwest Europe      | 11.2 (9.5 to 13.1)                  |
| Southeast Europe      | 13.9 (11.6 to 16.3)                 |
| North Africa/Middle East | 16.6 (12.8 to 20.8)                |
| Other Africa          |                                     |
| Southeast Asia        | 28.0 (23.4 to 33.0)                 |
| Northeast Asia        | 19.6 (15.5 to 24.2)                 |
| Other Asia            |                                     |
| Americas              |                                     |
| **Aged 65 to 74 years** |                                     |
| Australia             | 60.0 (57.0 to 63.1)                 |
| Other Oceania         | 69.4 (50.0 to 92.0)                 |
| Northwest Europe      | 44.0 (38.1 to 50.3)                 |
| Southeast Europe      | 58.5 (51.7 to 65.9)                 |
| North Africa/Middle East | 70.7 (54.5 to 89.1)                |
| Other Africa          |                                     |
| Southeast Asia        | 91.6 (71.0 to 114.7)                |
| Northeast Asia        | 95.7 (77.6 to 115.7)                |
| Other Asia            |                                     |
| Americas              |                                     |
| **Aged ≥75 years**    |                                     |
| Australia             | 180.9 (175.6 to 186.3)              |
| Other Oceania         | 211.1 (168.7 to 258.3)              |
| Northwest Europe      | 143.9 (132.5 to 155.8)              |
| Southeast Europe      | 174.5 (160.4 to 189.1)              |
| North Africa/Middle East | 212.8 (175.7 to 253.4)             |
| Other Africa          |                                     |

### Table 11. Continued

| Region of Birth      | ASR, WHO World Population (95% CI) |
|----------------------|-------------------------------------|
| Southeast Asia       | 280.7 (235.3 to 330.0)              |
| Northeast Asia       | 281.3 (242.3 to 323.1)              |
| Other Asia           |                                     |
| Americas             |                                     |

ASR indicates age-standardized rate; WHO, World Health Organization.

*To minimize small cell sizes when assessing interactions between age and region of birth and age and socioeconomic status, age categories were collapsed to 20-year age groups commencing from ≥25 years. Population data (ie, denominator information) for region of birth for the years 20 to 24 was unavailable.

†Cells based on sample sizes ≥10 or cells that can be used to deduce cells with ≥10 patients have been suppressed to protect patient privacy in accordance with local standards.
In this study, SES was correlated with overall, fatal, and nonfatal ICH attack rates but not with fatal ICH at 365 days for 30-day survivors. Our finding of an association with socioeconomic deprivation and fatal ICH incidence at 30 days is consistent with a recent study from France demonstrating an association between socioeconomic deprivation and stroke case mortality in the early postacute period (up to 90 days after stroke), specifically, after the first 2 weeks. As in France, Australia has a universal healthcare system with free access to public hospitals and thus minimal financial barriers to access acute care facilities; in the New South Wales health system, acute stroke is managed overwhelmingly in public hospitals, with only 1 private hospital offering an acute stroke unit. Access to

Table 12. ICH Risk Factors by Sex, Age, and SES

| Variable          | Median Age (IQR) | Hypertension | Diabetes | Cerebral Malignancies | Smoking | Alcohol/Drug Use | Renal Disease | Anticoagulant Use | AVMs/Other Malformations |
|-------------------|-----------------|--------------|----------|-----------------------|---------|------------------|---------------|-------------------|-------------------------|
| **Sex**           |                 |              |          |                       |         |                  |               |                   |                         |
| Male              | 73 (62 to 80)   | 64.1         | 14.5     | 3.7                   | 37.5    | 8.2              | 8.1           | 9.0               | 2.7                     |
| Female            | 79 (69 to 85)*  | 64.1         | 10.5*    | 1.9*                  | 18.4*   | 2.5*             | 5.1*          | 6.6*              | 1.9†                    |
| **Age (y)**       |                 |              |          |                       |         |                  |               |                   |                         |
| 20 to 39          | —               | 28.6         | 5.3      | 33.0                  | 18.9    | 5.3              | 19.2          |                   |                         |
| 40 to 49          | —               | 50.6         | 6.5      | 4.3                   | 39.7    | 17.4             | 5.6           | 3.2               | 8.6                     |
| 50 to 59          | —               | 64.4         | 12.0     | 5.3                   | 38.6    | 13.8             | 6.2           | 4.1               | 4.7                     |
| 60 to 69          | —               | 68.2         | 16.3     | 4.5                   | 40.9    | 8.4              | 7.0           | 8.1               | 2.2                     |
| 70 to 79          | —               | 67.6         | 15.9     | 2.7                   | 28.8    | 3.5              | 6.9           | 10.1              | 1.1                     |
| 80 to 89          | —               | 65.3         | 10.6     | 1.2                   | 19.2    | 1.1              | 8.8           | 8.6               | 0.5                     |
| ≥90               | —               | 59.2*        | 8.1*     | 10.1*                 | 4.9*    |                  |               |                   |                         |
| **IRSD (SES)**    |                 |              |          |                       |         |                  |               |                   |                         |
| Quintile 1 (low)  | 75 (63 to 81)   | 66.6         | 14.5     | 3.0                   | 28.9    | 6.1              | 8.1           | 5.1               | 2.0                     |
| Quintile 2        | 75 (63 to 82)   | 65.2         | 13.9     | 2.8                   | 29.9    | 4.6              | 7.0           | 9.5               | 2.3                     |
| Quintile 3        | 75 (65 to 82)   | 63.6         | 14.1     | 3.0                   | 29.6    | 5.7              | 6.1           | 8.0               | 1.9                     |
| Quintile 4        | 76 (65 to 83)   | 63.3         | 11.2     | 2.5                   | 29.6    | 5.4              | 7.2           | 8.2               | 2.6                     |
| Quintile 5 (high) | 78 (68 to 85)*  | 63.8         | 10.9*    | 2.8                   | 23.7*   | 4.9              | 5.7*          | 7.9*              | 2.5                     |
| **Region of birth**|                |              |          |                       |         |                  |               |                   |                         |
| Australia         | 77 (66 to 84)   | 62.1         | 10.9     | 3.2                   | 27.9    | 5.9              | 6.1           | 8.1               | 2.3                     |
| Oceania           | 63 (51 to 77)   | 67.4         | 15.2     | 1.9                   | 27.9    | 5.1              | 8.3           | 7.6               | 2.3                     |
| Northwest Europe  | 78 (69 to 84)   | 63.2         | 10.1     | 3.2                   | 34.7    | 4.8              | 5.1           | 8.5               | 1.5                     |
| Southeast Europe  | 76 (69 to 82)   | 69.5         | 19.8     | 1.9                   | 29.3    | 3.6              | 10.1          | 7.7               | 1.2                     |
| North Africa/Middle East | 73 (62 to 79) | 76.3 | 28.8 | 1.9 | 33.1 | 9.3 | 5.4 | | |
| Other Africa      | 75.5 (62.83)    | 68.2         | 1.9      | 19.7                  | 17.6    | 10.1             | 9.1           | 9.7               | 1.9                     |
| Southeast Asia    | 67 (52 to 78)   | 74.3         | 16.0     | 1.9                   | 20.7    | 8.4              | 4.7           | 3.4               |                         |
| Northeast Asia    | 73 (63 to 81)   | 71.4         | 14.3     | 1.9                   | 20.0    | 7.3              | 5.7           |                   |                         |
| Other Asia        | 68 (55 to 78)   | 74.1         | 18.8     | 1.9                   | 17.6    |                  | 11.0*         |                   |                         |
| Americas          | 65.5 (58 to 76)*| 60.0*        | 20.0*    | 1.9*                  | 38.0*   | 11.0*            |               |                   |                         |

AVM indicates arteriovenous malformation; ICH, intracerebral hemorrhage; IRSD, Index of Relative Socio-Economic Disadvantage; IQR, interquartile range; SES, socioeconomic status. *P < 0.001. †P = 0.006. ‡Cells based on sample sizes <10 or cells that can be used to deduce cells with <10 patients have been suppressed to protect patient privacy in accordance with local standards. §P = 0.05. kP = 0.008. All risk factors ascertained using International Classification of Diseases, 10th revision-coded comorbidities recorded during the admission and in any hospital admission that occurred during the 6 months prior to the ICH admission with the exception of anticoagulant use, where recorded use in the current ICH acute admission was ascertained.
postacute care, rehabilitation, and community support services may be more variable, providing patients with greater resources and possibly influencing survival in the postacute period. That SES did not affect 365-day mortality for 30-day survivors in our study may reflect that ICH survivors are more homogenous in their SES compared with patients who die from ICH.

ICH risk due to socioeconomic disadvantage was not evident among people aged >80 years, suggesting that the influence of SES may wane with increasing age. Alternatively, geographically derived estimates of SES among the elderly may be subject to misclassification because retirement and aged-care facilities may skew scores in their geographic locations. Location of residence was used to determine SES rather than individually assessed indicators of affluence; therefore, our finding may be vulnerable to an ecological fallacy. However, identifying geographic pockets of stroke risk allows targeting of health services and clinicians to provide services in areas in need.

Metrics of stroke mortality include case fatality \(^1,2\); mortality rates calculated using cause of death data; and, as we have done, calculation of fatal incidence or attack rates, selecting patients with an acute presentation of stroke who die within a defined period (eg, 30 days).\(^49,50\) Determining the burden of fatal ICH in the population requires reference to population denominators, and our results demonstrate heightened burden within subgroups. We found that fatal ICH rates are higher for men, increase with age, and vary according to region of birth and SES.

Limitations

Exhaustive case ascertainment and clinician-validated stroke diagnoses are methodological strengths of gold standard epidemiological stroke studies that cannot be matched by research using administrative health data; however, administrative data sets cost-effectively collect health information continuously over time for large jurisdictions yielding high numbers of cases.\(^5\)

The available evidence supports high levels of coding accuracy in Australia. In general, positive predictive values of principal diagnoses in Australian data sets are high (>90%) and are often ≥95%,\(^18,24,54–57\) with extensive formal training of coders, routine auditing, and high levels of interrater reliability.\(^21\) Two Australian validation studies reported high positive predictive values of principal stroke diagnostic codes (95%\(^24\) and 96%\(^56\)), with 1 study attributing all inaccuracies to clinician-validated ischemic strokes being assigned an ICD code for unspecified stroke.\(^56\) Because this study determined attack rates of stroke and its subtypes, the validation analysis implies that stroke subtypes including ICH were coded accurately in all cases except for ischemic stroke. Although the sensitivity of Australian stroke coding has not been specifically reported, researchers have validated diagnostic coding of stroke mimics, including transient ischemic attack, migraine with hemiparesis, and hypoglycemia, to determine whether strokes were misclassified as such.\(^24\) None of these events were considered to be strokes on clinician review, indicating that sensitivity is likely to be high.

These Australian results concur with international reports of high levels of accuracy for stroke coding and, specifically, ICH coding. The specificity and positive predictive value of a principal ICH diagnosis was reported in a US study to be 96% and 89%, respectively.\(^58\) In Canada and England, the positive predictive value of ICH ICD-10 stroke coding has been reported as 98% and 95.9%, respectively.\(^59,60\) A systematic review including the US and Canadian study cited above reports positive predictive values of 92% and 100% of a principal ICH diagnosis in an additional 2 studies.\(^61\)

In France, researchers citing unpublished data reported very high levels of sensitivity and specificity of stroke coding (96% and 93%, respectively)\(^30\) and in Sweden, the sensitivity of stroke hospitalization coding has been reported to be 89.3% for definite or possible strokes according to Multinational Monitoring of Determinants and Trends in Cardiovascular Disease (MONICA).\(^16\) An Italian study noted positive predictive values of principal and secondary ICH codes between 81% and 86%; the inclusion of secondary codes would have likely resulted in some misclassification, given reports that secondary codes reduce coding accuracy.\(^62\) The sensitivity of principal ICH diagnoses has been reported to be 85% (ICD-9),\(^59\) 87.9% (ICD-10),\(^63\) and 78% (ICD-9),\(^64\) with the authors of the latter study noting potential misclassification in the gold standard, which would have contributed to inaccuracies. We acknowledge that high levels of accuracy have not been universally reported. One study validated ICD-10 ischemic stroke coding, reporting high positive predictive value of 95.1% but low sensitivity of 67.3%\(^65\); these results may not be generalizable to ICH coding because higher levels of accuracy have been reported for hemorrhagic compared with ischemic stroke coding.\(^58,59,62\) Although sensitivity of ICH principal diagnoses were reported to be high (87.9%) in 1 French study,\(^63\) the positive predictive value and false-positive and false-negative rates were reported to be 64.8%, 16.2%, and 7.0%, respectively. However, this study also reported substantially improved positive predictive values of stroke coding over a 5-year period (from 54.3% to 81.2%), in line with increasing coder experience of a recently implemented costing model using hospital administrative data.

In Australia and elsewhere (eg, United Kingdom, United States, New Zealand, Sweden), principal diagnoses reflect the main reason for the patient admission; however, in other jurisdictions, including France until 2009 and Italy, the main condition noted in administrative data sets reflects the
condition that consumes the most resources during the hospital stay. It has been suggested that such a resource use criteria for defining the main condition may underascertain cases. We note that variability in the reported accuracy across jurisdictions may be caused by several factors including the use of different definitions of a principal diagnosis; differences in the classification system used and in defining gold standards; validation of principal diagnosis versus both principal and secondary diagnoses; the length of time administrative coding has been used to enable financial reimbursement; and stroke subtype, with hemorrhagic stroke coding generally found to be more accurate than ischemic stroke.

We included only principal ICH diagnoses, as elsewhere, and thus may have underenumerated ICH if cases were not coded in the primary diagnostic position; however, the positive predictive value of principal ICH codes is high (89% to 98%), the length of time administrative coding has been used to enable financial reimbursement; and stroke subtype, with hemorrhagic stroke coding generally found to be more accurate than ischemic stroke.

Comorbidities tend to be underenumerated when compared with the original medical records but are coded with very low false-positive rates (<0.3%), although 1 recent Australia study using New South Wales hospital admissions data—as we have done—found that comorbidities ascertained from administrative data correlated well with medical records. Furthermore, we applied the maximum available look-back period of 6 months to minimize underascertainment and capture diagnoses recorded in those previous hospital attendances. Although a longer look-back period would have further maximized capture, more proximally experienced risk factors may have had greater impact on ICH risk and patient outcomes than those that could have been identified only in the more distant medical history.

We cannot exclude the possibility that temporal changes in coding may have influenced our findings. We considered hospital admission rates as proxies for attack rates and acknowledge that deaths occurring outside the hospital due to an acute ICH or mild cases not reaching the hospital would have been missed. Internationally, it has been reported that very few ICH cases are not hospitalised, and the percentage of out-of-hospital strokes in Australia has been declining over time. The Perth Community Stroke Study reported declines in out-of-hospital strokes from 21.5% in 1989–1990 to 7.7% in 2000–2001, and another Australian study carried out in 2009–2010 reported that only 4% of strokes do not reach the hospital. This trend would have underestimated our reported average annual decline in ICH rates. Furthermore, during the study period, health services in New South Wales experienced a growth of funding in stroke care that was conditional upon providing greater inpatient access for stroke patients. A series of state government task forces particularly addressed equitable access to stroke services and provided additional funding and resources linked to evidence-based practices and pathways beginning in emergency departments to ensure that patients with focal neurological symptoms, syncope, and headaches were directed to specialist inpatient services (http://www.aci.health.nsw.gov.au/networks/stroke/about). During the study period, hospitals in our health service received recurrent funding to support the implementation of stroke units and noted increases in the numbers of stroke admissions to these units. Education of general practitioners and members of the local community was undertaken to increase community and primary care services for focal neurological symptoms and the need for their urgent referral to the hospital. Consequently, in the health service under study, a trend toward greater resources and admissions would have under estimated declining admission rates in our study.

Hospitalized cases transferred outside the region may have been lost to follow-up because state-based death registries do not record deaths of persons dying outside their state of residence unless requested by family; however, there were few transfers (1.8%), and it is likely that patients with better prognoses are transferred for treatment and/or rehabilitation, having survived the acute period. We may have underestimated variation in stroke risk according to region of birth because first-generation Australian residents may share risk factors with their immigrant parents. Furthermore, nationality at birth does not necessarily reflect the cultural and linguistic diversity within countries that may also affect stroke risk.

Conclusion

We report falling overall and fatal ICH rates, which have rarely been reported. These decreases may reflect the impact of cardiovascular prevention measures and innovations in health service delivery. Men, those living in areas of relatively greater socioeconomic disadvantage, and those born in some regions of the world were at heightened risk of ICH and of dying from it.

Disclosures

John Worthington is currently medical co-chair of Stroke Services, New South Wales, an honorary leadership position tasked with executive decision making regarding stroke services.

References

1. van Asch CJ, Luitse MJA, Rinkel GJE, van der Tweel I, Algra A, Klijn CJM. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol. 2010;9:167–176.
2. Islam MS, Anderson CS, Hankey GJ, Hardie K, Carter K, Broadhurst R, Jamrozik K. Trends in incidence and outcomes of stroke in Perth, Western

DOI: 10.1161/JAHA.114.001161

Epidemiology of Intracerebral Hemorrhage Gattellari et al

ORIGINAL RESEARCH
16. K
15. Thrift AG, Dewey HM, Macdonell RA, McNeill JJ, Donnan GA. Incidence of stroke subtypes in the North East Coast of Australia. Stroke. 2003;34:2087–2092.
15. Thrift AG, Dewey HM, Macdonell RA, McNeill JJ, Donnan GA. Stroke incidence on the East Coast of Australia. Stroke. 2000;31:1196–1199.
15. Thrift AG, Dewey HM, Macdonell RA, McNeill JJ, Donnan GA. Stroke incidence on the East Coast of Australia. Stroke. 2000;31:1196–1199.
16. K
15. Thrift AG, Dewey HM, Macdonell RA, McNeill JJ, Donnan GA. Incidence of stroke subtypes in the North East Coast of Australia. Stroke. 2003;34:2087–2092.
15. Thrift AG, Dewey HM, Macdonell RA, McNeill JJ, Donnan GA. Stroke incidence on the East Coast of Australia. Stroke. 2000;31:1196–1199.
Epidemiology of Intracerebral Hemorrhage

47. Tran J, Mirzaei M, Anderson L, Leeder SR. The epidemiology of stroke in the Middle East and North Africa. *J Neurol Sci*. 2010;295:38–40.

48. Azaepazhooh MR, Etemadi MM, Donnan GA, Mokhber N, Majdi MR, Ghayour-Mobarhan M, Ghaneh-Khay K, Farzadfar MT, Kiani R, Panahandeh M, Thrift AG. Excessive incidence of stroke in Iran: evidence from the Mashhad Stroke Incidence Study (MSIS), a population-based study of stroke in the Middle East. *Stroke*. 2010;41:e3–e10.

49. Thrift AG, Dewey HM, Sturm JW, Paul SL, Gilligan AK, Srikantik V, Macdonell RA, McNeil JJ, Macleod MR, Donnan GA. Greater incidence of both fatal and nonfatal strokes in disadvantaged areas: the Northeast Melbourne Stroke Incidence Study. *Stroke*. 2006;37:877–882.

50. Cesaroni G, Agabiti N, Forastiere F, Perucci CA. Socioeconomic differences in stroke incidence and prognosis under a universal healthcare system. *Stroke*. 2009;40:2812–2819.

51. Addo J, Ayerbe L, Mohan KM, Crichton S, Chelden A, Chen R, Chen R, Wolfe CD, McKevitt C. Socioeconomic status and stroke: an updated review. *Stroke*. 2012;43:1186–1191.

52. Heeley E, Wei J, Carter K, Islam M, Thrift A, Hankey G, Cass A, Anderson CS. Socioeconomic disparities in stroke rates and outcome: pooled analysis of stroke incidence studies in Australia and New Zealand. *Med J Aust*. 2011;195:10–14.

53. Grimaud O, Leray E, Lallou E, Agharfiz R, Durier J, Giroud M, Béjot Y. Mortality following stroke during and after acute care according to neighbourhood deprivation: a disease registry study. *J Neurol Neurosurg Psychiatry*. 2014;85:1313–1318.

54. Teng TH, Finn J, Geelhoed E, Hobbs M. A validation study: how effective is the Hospital Morbidity Data as a surveillance tool for heart failure in Western Australia? *Aust N Z J Public Health*. 2008;32:405–407.

55. Brameld KJ, Thomas MAB, Holman CDJ, Bass AJ, Rouse IL. Validation of linked administrative data on end-stage renal failure: application of record linkage to a ‘clinical base population’. *Aust N Z J Public Health*. 1999;23:464–467.

56. Wang Y, Levi CR, Attila JR, D’Este CA, Spratt N, Fisher J. Seasonal variation in stroke in the Hunter region, Australia: a five-year hospital-based study, 1995–2000. *Stroke*. 2003;34:1144–1150.

57. Lee AH, Somerford PJ, Yau KKW. Risk factors for ischaemic stroke recurrence after hospitalisation. *Med J Aust*. 2004;181:244–246.

58. Tirschwell DL, Longstreth WT Jr. Validating administrative data in stroke research. *Stroke*. 2002;33:2465–2470.

59. Kokotaio RA, Hill MD. Coding of stroke and stroke risk factors using International Classification of Diseases, Revisions 9 and 10. *Stroke*. 2005;36:1776–1781.

60. Kirkman MA, Mahattanakul W, Gregson BA, Mendelow AD. The accuracy of hospital discharge coding for hemorrhagic stroke. *Acta Neurol Belg*. 2009;109:114–119.

61. Andrade SE, Harrol DR, Tija J, Cutrona SL, Szczynski JS, Dodd KS, Goldberg RJ, Gurwitz JH. A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data. *Pharmacoepidemiol Drug Saf*. 2012;21(5):100–128.

62. Palmieri L, Barchielli A, Cesana G, de Campora E, Goldoni CA, Spalaceto P, Ugucioni M, Varcheri F, Vanuzzo D, Ciccarelli P, Giampaoli S; Research Group of the Project ‘Italian National Register of Coronary and Cerebrovascular Events. The Italian register of cardiovascular diseases: attack rates and case fatality for cerebrovascular events. *Cerebrovasc Dis* 2007;24:530–539.

63. Aboa-Eboulé C, Mengue D, Benzenine E, Hommel M, Giroud M, Béjot Y, Quantin C. How accurate is the reporting of stroke in hospital discharge data? A pilot validation study using a population-based stroke registry as control. *J Neurol*. 2013;260:605–613.

64. Jones SA, Gottesman RF, Shahar E, Wruck L, Rosamond WD. Validity of hospital discharge codes for stroke: the Atherosclerosis Risk in Communities Study. *Stroke*. 2014;45:3219–3225 doi:10.1161/STROKEAHA.114.006316–/DC1.

65. Haesebeart J, Termoz A, Polazi S, Mouchoux C, Mecullof L, Derex L, Nighoghossian N, Schott AM. Can hospital discharge databases be used to follow ischemic stroke incidence? *Stroke*. 2013;44:1770–1774.

66. Quan H, Moskal LK, Forster AJ, Brien S, Walke R, Romano PS, Sundararajan V, Buring N, Henriksso N, Steinouo O, Droesler S, Pincus HA, Ghali WA. International variation in the definition of the “main condition” in ICD-coded health data. *Int J Qual Health Care*. 2014;26:511–515.

67. Leyden JM, Klenig T, Newbury J, Castle S, Cranefield J, Anderson CS, Crotty M, Whitford D, Jannes J, Lee A, Greenhill J. Adelaide stroke incidence study: declining stroke rates but many preventable cardioembolic strokes. *Stroke*. 2013;44:1226–1231.

68. Cadilhac DA, Pearce DC, Levi CR, Donnan GA. Improvements in the quality of care and health outcomes with new stroke care units following implementation of a clinician-led, health system redesign programme in New South Wales, Australia. *Qual Saf Health Care*. 2008;17:329–333.

69. Katzenellenbogen JM, Vos T, Somerford P, Begg S, Semmens JB, Codde JP. Burden of stroke in indigenous Western Australians: a study using data linkage. *Stroke*. 2011;42:1515–1521.